Phase 3 Recruiting Network
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…
Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
+ 563 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of s…
Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
+ 198 more sites in the U.S.
Phase 3 Recruiting Network
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…
Sponsor: GOG Foundation
NCT ID: NCT05659381
Locations: - City of Hope — Duarte, California
- University of California San Diego Moores Cancer Center — La Jolla, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
+ 56 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07214779
Locations: - Alaska Womens Cancer Care Akwcc — Anchorage, Alaska
- University of Arizona Cancer Center — Tucson, Arizona
- City of Hope Medical Center — Duarte, California
+ 54 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Locations: - Alaska Women's Cancer Care — Anchorage, Alaska
- Yale University School of Medicine — New Haven, Connecticut
- Sylvester Comprehensive Cancer Center at Lennar — Coral Gables, Florida
+ 40 more sites in the U.S.
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Locations: - HonorHealth — Phoenix, Arizona
- University of Arkansas — Little Rock, Arkansas
- UCLA Health — Los Angeles, California
+ 35 more sites in the U.S.
Phase 3 Recruiting Industry
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Locations: - University of Alabama at Birmingham ( Site 0006) — Birmingham, Alabama
- Alaska Women's Cancer Care ( Site 0096) — Anchorage, Alaska
- UCSF Medical Center at Mission Bay ( Site 0013) — San Francisco, California
+ 33 more sites in the U.S.
Phase 3 Recruiting Industry
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…
Sponsor: Genelux Corporation
NCT ID: NCT05281471
Locations: - The University of South Alabama, Mitchell Cancer Institute — Mobile, Alabama
- University of Arizona Cancer Center — Tucson, Arizona
- City of Hope — Duarte, California
+ 30 more sites in the U.S.
Phase 3 Recruiting Industry
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Locations: - Disney Family Cancer Center — Burbank, California
- Scripps Clinic — La Jolla, California
- Palo Alto Medical Foundation — Palo Alto, California
+ 29 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Locations: - University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
- Cleveland Clinic Foundation - Florida — Weston, Florida
- Massachusetts General Hospital — Boston, Massachusetts
+ 10 more sites in the U.S.
Phase 3 Recruiting Industry
This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is p…
Sponsor: NX Development Corp
NCT ID: NCT05804370
Locations: - Mayo Clinic Arizona — Phoenix, Arizona
- Mayo Clinic Florida — Jacksonville, Florida
- Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
+ 8 more sites in the U.S.
Phase 3 Recruiting Industry
This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.
Sponsor: Imunon
NCT ID: NCT06915025
Locations: - Advent Health — Orlando, Florida
- Louisiana State University HSC - NO Cancer Center — New Orleans, Louisiana
- Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota
+ 6 more sites in the U.S.